301230 Pharmaresources
- 34.92
- -1.18-3.27%
Pharmaresources News
Express News | Hongbo Pharmaceutical: Shareholder Dingtai Haifu plans to reduce holdings by no more than 1%
Open Source Securities released a research report on April 25 stating that it gave Hongbo Pharmaceutical (301230.SZ) a purchase rating. The main reasons for the rating include: 1) steady overall revenue growth, with short-term profit fluctuations due to f
Open Source Securities released a research report on April 25 stating that it gave Hongbo Pharmaceutical (301230.SZ) a purchase rating. The main reasons for the rating include: 1) steady overall revenue growth, with short-term profit fluctuations due to falling prices of core API products; 2) steady development of the drug discovery business, with the CAD/AIDD platform continuing to empower customer new drug projects; 3) continuing to increase marketing and promotion efforts, and the expected rapid release of core API products. (Mainichi Keizai Shimbun)
Hongbo Pharmaceutical (301230.SZ): Net profit of 3.667,700 yuan in the first quarter decreased by 75.99% year-on-year
On April 25, Ge Longhui Pharmaceutical (301230.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 131 million yuan, up 7.69% year on year; net profit attributable to shareholders of listed companies was 36.677 million yuan, down 75.99% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 625,500 yuan, down 95.45% year on year; basic earnings per share were 0.03 yuan.
The CRO sector declined at the beginning of the market. Jinkai Biotech fell more than 10%, while Hongbo Pharmaceuticals, Tiger Pharmaceuticals, Nootai Biotech, Gloria, and Pharmaceutical Stone Technology followed suit.
The CRO sector declined at the beginning of the market. Jinkai Biotech fell more than 10%, while Hongbo Pharmaceuticals, Tiger Pharmaceuticals, Nootai Biotech, Gloria, and Pharmaceutical Stone Technology followed suit.
Hongbo Pharmaceutical (301230.SZ) announced its 2023 annual results, with net profit of 376.192 million yuan, a year-on-year decrease of 44%
Hongbo Pharmaceutical (301230.SZ) announced its 2023 annual results. The company achieved operating income of 4.9 during the period...
Express News | Since April, nearly 10 listed companies have announced illegal short-term transactions involving senior directors and supervisors
The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit
The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit
Hongbo Pharmaceutical (301230.SZ): A total cost of 178.587 million yuan to buy back 0.5847% of the shares
Gelonghui, April 1, 丨 Hongbo Pharmaceutical (301230.SZ) announced that as of March 31, 2024, the company had repurchased a total of 629,300 shares through a dedicated securities account, accounting for 0.5847% of the company's current total share capital of 107,622,666 shares. The highest transaction price was 37.68 yuan/share, and the lowest transaction price was 26.82 yuan/share. The total transaction amount was 17,858,707.12 yuan (excluding transaction fees).
A-shares CRO concept stocks fluctuated and declined
Gelonghui, March 21 | Hongbo Pharmaceutical and Chengdu Pioneer fell more than 4%, while many stocks such as Medici, Wisdom Pharmaceutical, and Wanbang Pharmaceutical fell.
Smart medicine and innovative drug concepts are active, and many stocks such as Berry Gene have risen and stopped
Gelonghui, March 18 | Hongbo Pharmaceutical rose more than 15%. Berry Gene, Jinan Hi-Tech, and Saili Medical rose and stopped, while Langma Information, Pharmaceutical Technology, Chengdu Pioneer, and Wisdom Pharmaceuticals rose ahead. According to news, at the Nvidia GTC conference, which will open on the 18th, there are 90 healthcare/life sciences-related events — the highest number of all industries, surpassing popular fields such as automobiles, cloud services, and hardware/semiconductors.
The A-share CRO sector declined at the beginning of the session, and Hongbo Pharmaceutical fell more than 8%
Glonghui, March 15 | Hongbo Pharmaceutical fell more than 8%, followed by Baihua Pharmaceutical, Norsgate, Pharmaceutical Kangde, and Jinkai Biotech.
Dragon Tiger List丨Hongbo Pharmaceutical rose 11.48%, and the four institutions had net sales of 94.2836 million yuan
Gelonghui, March 14 | Hongbo Pharmaceutical (301230.SZ) rose 11.48% today, with a turnover of 672 million yuan and a turnover rate of 27.39%. According to Dragon Tiger List data, “Fang Xinxia” bought three seats, with a net purchase of 12.069 million yuan; the four institutions bought 204.787 million yuan and sold 115 million yuan at the same time, for a total net sale of 94.2836 million yuan.
A-share changes丨The innovative drug sector rallied in the afternoon, leading the way in AI pharmaceuticals
Gelonghui, March 13 | The innovative drug sector in the A-share market rose in the afternoon, leading in the direction of AI pharmaceuticals. Hongbo Pharmaceutical rose more than 10%, while Chengdu Pioneer, Kain Technology, Zhixiang Jintai, Maiwei Biotech, and Alice followed suit. According to the news, recently, Insilicon Intelligence, one of the unicorns of AI pharmaceuticals in China, published a research paper in the “Nature-Biotech” magazine, revealing the entire process of the TNIK inhibitor developed by the company using artificial intelligence, from target discovery to phase II clinical development, and disclosed for the first time the pre-clinical and clinical trial data of this AI drug.
CRO concept stocks fluctuated higher, Wisdom Pharmaceuticals rose more than 8%
Gelonghui, March 12 | Wisdom Pharmaceuticals rose more than 8%, followed by Hongbo Pharmaceutical, Pharmaceutical Pharmaceutical, Medici, and Tailong Pharmaceutical.
Express News | Hongbo Pharmaceutical: Shareholder Zhongfu Cornerstone plans to reduce holdings by no more than 1%
Hongbo Pharmaceutical (301230) Depth: A one-stop comprehensive service provider focusing on the drug discovery stage
Key investment points: We have been deeply involved in the field of small molecules for many years, and orders have continued to grow. Hongbo Pharmaceutical is a one-stop CXO for the development and production of innovative small molecule drugs. The company builds core competitiveness around drug design, uses design ability as the core competitive advantage, and is deeply involved in customers
Hongbo Pharmaceutical (301230.SZ): Initial repurchase of 140,300 shares involving 3.9938 million yuan
Gelonghui, Feb. 21丨Hongbo Pharmaceutical (301230.SZ) announced that on February 20, 2024, for the first time, the company repurchased 140,300 shares of the company's shares through a special stock repurchase securities account, accounting for 0.13% of the company's current total share capital. The highest transaction price was 28.50 yuan/share, the lowest transaction price was 28.28 yuan/share, and the total transaction amount was 3.9938 million yuan (excluding transaction fees).
Express News | Nearly 30 listed companies announced plans to repurchase or increase holdings up to 100 million yuan after the market, and Aijian Group's repurchase was used for cancellation
Hongbo Pharmaceutical (301230.SZ): plans to spend 50 million yuan to 100 million yuan to buy back the company's shares
On February 19, Ge Longhui Pharmaceutical (301230.SZ) announced that the company plans to use its own funds to repurchase RMB common stock (A shares) shares already issued by the company through centralized bidding transactions for subsequent implementation of equity incentives or employee stock ownership plans. The company plans to use its own capital of not less than RMB 50 million (inclusive) and no more than RMB 10 million (inclusive) for repurchases. The price range for repurchasing shares does not exceed RMB 45.00 per share (inclusive). Based on the maximum repurchase price of 45.00 yuan/share and the lower limit of the total repurchase capital of RMB 50 million (inclusive), it is estimated
CRO concept stocks boosted, and Hongbo Pharmaceutical rose more than 14%
Gelonghui, Feb. 1 | Hongbo Pharmaceutical rose more than 14%, Haofan Pharmaceutical rose more than 7%, and Gloria, Puli Pharmaceuticals, and Medici followed suit.
Analysis
Price Target
No Data
